Syneos Health™, the only fully integrated biopharmaceutical solutions organization, today announced that the company is a founding member of Align Clinical CRO. This new industry technology standards group is dedicated to making it easier for the life sciences industry to run clinical trials with CROs to bring products to market faster and more efficiently.
“Smart collaboration – identifying better and faster methods to deliver medicines to patients – is at the heart of everything we do at Syneos Health,” says Rachel Stahler, Chief Information Officer. “Within our organization, we’ve purposefully removed the silos between the clinical and commercial disciplines to provide solutions that improve operational delivery and enable our customers to speed therapies to patients. We’re thrilled to bring this spirit of collaboration to Align Clinical CRO, where we’ll work in partnership with our industry peers to transform clinical trial execution.”
Align Clinical CRO represents a first-ever global effort where CROs are joining forces to develop open technology standards to transform clinical trial operations. The organization, which launched today, brings together six leading CROs planning to help create open technology standards intended to simplify trial execution and improve the productivity and efficiency of clinical trials for sponsors.
Syneos Health brings deep industry knowledge to Align Clinical CRO, including in-depth clinical and commercial expertise and integrated, multi-disciplinary perspectives. This knowledge transfer also includes technology competencies such as clinical data systems, as well as commercial insights that can inform accelerated trial design and execution.
“There’s tremendous potential to enhance clinical trial execution through common technology standards that will benefit the entire industry,” said Henry Levy, President of Align Clinical CRO. “Align Clinical CRO represents an important industry collaboration to improve the trial processes and how the industry works together to accelerate drug development.”
